<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2706">
  <stage>Registered</stage>
  <submitdate>11/03/2010</submitdate>
  <approvaldate>11/03/2010</approvaldate>
  <nctid>NCT01088191</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction</studytitle>
    <scientifictitle>Phase 2 Study to Assess Safety &amp; Tolerability of a Single Injection Into the Knee Joint of Two Different Doses of MSB-CAR001 Combined With Hyaluronan Compared to Hyaluronan Alone in Patients Who Have Undergone an ACL Reconstruction</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MSB-CAR001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anterior Cruciate Ligament Injury</healthcondition>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MSB-CAR001 Combined With Hyaluronan
Treatment: drugs - Hyaluronan

Active Comparator: Hyaluronan Alone - Hyaluronan Alone

Experimental: MSB-CAR001 - Single Dose of MSB-CAR001 Combined With Hyaluronan


Other interventions: MSB-CAR001 Combined With Hyaluronan
Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan
Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan

Treatment: drugs: Hyaluronan
Hyaluronan alone

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the overall safety of MSB-CAR001 plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the overall efficacy with MSB-CAR001 plus Hyaluronan compared to Hyaluronan alone using MRI scans and x-ray of the involved knee joint and access the change in outcomes (KOOS, SF-36) and pain (VAS)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Males or females at least 18 years of age, but not older than 40

          2. ACL injury requiring reconstruction

          3. Have undergone unilateral ACL reconstruction surgery within six months of injury;

          4. Willing and able to undertake a standardized rehabilitation protocol

          5. ACL graft used is autograft

          6. Willingness to participate in follow-up for 24 months from the time of initial
             treatment

          7. Ability to understand and willingness to sign consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Women who are pregnant or breast feeding or planning to become pregnant during the
             study

          2. Previous allergic reaction to Hyaluronan

          3. Systemic or local infection at the screen visit or at the time of the study injection

          4. History of any autoimmune disease, such as, systemic lupus erythematosus, Addison's
             disease, Crohn's disease, or rheumatoid arthritis

          5. Treatment with immunosuppression therapy within 6 months prior to screen (visit 1)

          6. Acute or chronic infectious disease, including but not limited to human
             immunodeficiency virus (HIV);

          7. Treatment and /or uncompleted follow-up treatment of any investigational therapy
             within 6 months before the procedure and /or intent to participate in any other
             investigational drug or cell therapy study during the 24 month follow-up period of
             this study;

          8. Recipient of prior allogeneic stem cell/progenitor cell therapy

          9. Undergoing a simultaneous procedure to the opposite knee

         10. 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody
             specificities to donor HLA antigens;

         11. Known sensitivities to bovine (cow), murine (mouse), chicken products and/or
             dimethylsulfoxide (DMSO). Previous allergic reaction to Hyaluronan;

         12. History or current evidence of alcohol or drug abuse or is a recreational user of
             illicit drugs or prescription medications

         13. History of prior surgery to the study knee joint

         14. History of malignancy (excluding basal cell carcinoma that has been successfully
             excised)

         15. Chondral lesions noted at time of surgical reconstruction greater than Grade 1a on any
             surfaces</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>17</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Emeritus Research - Malvern East</hospital>
    <postcode>3145 - Malvern East</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mesoblast, Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate safety and preliminary efficacy of MSB-CAR001 in
      subjects who have recently undergone an Anterior Cruciate Ligament Reconstruction</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01088191</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Donna Skerrett, MD</name>
      <address>Mesoblast, Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>